Thermo Fisher Scientific secures USFDA nod for Oncomine Dx Target Test for lung cancers with HER2 mutations

Lung cancer is the leading cause of cancer death among both men and women in the United States. For patients with metastatic NSCLC, prognosis is particularly poor, as only 8% of patients will live beyond five years after diagnosis. HER2-mutant NSCLC occurs in approximately 2-4% of patients with non-squamous NCSLC, and Enhertu is the first HER2-directed therapy for patients with NSCLC approved in the U.S.

"With care decisions increasingly made based on a tumor's molecular profile, the FDA's latest approval of ENHERTU in HER2 mutant metastatic non-small cell lung cancer and the additional approval of the Oncomine Dx Target Test as a companion diagnostic marks a significant step forward for precision oncology," said Garret Hampton, president, clinical next-generation sequencing and oncology at Thermo Fisher Scientific. "To ensure patients and clinicians can readily access testing to inform care decisions, we are committed to making NGS accessible and easy to use so patients everywhere will be able to benefit from precision therapies, when indicated."

The Oncomine Dx Target Test is designed to simultaneously evaluate 23 genes associated with NSCLC. The test received its first approval by the FDA as a CDx in 2017. In the US alone, it is approved for seven targeted therapies for NSCLC and one for cholangiocarcinoma.

Read also: AstraZeneca Enhertu secures USFDA nod for HER2-low breast cancer